Compare Quest Diagnostics Inc (DGX) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Snap Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Snap Inc trades at $5.87 (market cap $9.83B). The key difference: Quest Diagnostics Inc is far larger — about 2.5× Snap Inc's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Snap Inc for 68 Days on average.
| DGX | SNAP | |
|---|---|---|
Market Cap | $25.06B | $9.83B |
Volume | 927,361 | 28,532,342 |
Sector | Health | Media |
52-Week High | $247.45 | $9.09 |
52-Week Low | $173.49 | $3.93 |
Typical Hold Time | 56 Days | 68 Days |
Enterprise Value | $30.82B | $11.39B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Snap Inc. (SNAP) trades at $5.865, up 1.12% with a bullish technical signal. Revenue grew to $5.93B in 2025, though net losses persist at -$460M. Recent news highlights AI integration in SPECS glasses via partnerships with NVIDIA and Salesforce. Analyst consensus is mixed with 38% buy ratings and a $7.78 price target.
Outlook: Potential upside exists from AI initiatives and revenue growth, but profitability challenges and high debt ($3.61B) pose risks. The stock's valuation (P/S 1.55) appears reasonable, yet investor caution is warranted amid regulatory pressures and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
